Cargando…

Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial

BACKGROUND: Cognitive impairment affects 50%–75% of people with secondary progressive multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate earlier intervention. OBJECTIVE: The main aim of this study was to assess the relationship between longitudinal changes...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Thomas, Tur, Carmen, Eshaghi, Arman, Doshi, Anisha, Chan, Dennis, Binks, Sophie, Wellington, Henny, Heslegrave, Amanda, Zetterberg, Henrik, Chataway, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493411/
https://www.ncbi.nlm.nih.gov/pubmed/35946107
http://dx.doi.org/10.1177/13524585221114441
_version_ 1784793712626237440
author Williams, Thomas
Tur, Carmen
Eshaghi, Arman
Doshi, Anisha
Chan, Dennis
Binks, Sophie
Wellington, Henny
Heslegrave, Amanda
Zetterberg, Henrik
Chataway, Jeremy
author_facet Williams, Thomas
Tur, Carmen
Eshaghi, Arman
Doshi, Anisha
Chan, Dennis
Binks, Sophie
Wellington, Henny
Heslegrave, Amanda
Zetterberg, Henrik
Chataway, Jeremy
author_sort Williams, Thomas
collection PubMed
description BACKGROUND: Cognitive impairment affects 50%–75% of people with secondary progressive multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate earlier intervention. OBJECTIVE: The main aim of this study was to assess the relationship between longitudinal changes in cognition and baseline serum neurofilament light chain (sNfL) in PwSPMS. In a multi-modal analysis, MRI variables were additionally included to determine if sNfL has predictive utility beyond that already established through MRI. METHODS: Participants from the MS-STAT trial underwent a detailed neuropsychological test battery at baseline, 12 and 24 months. Linear mixed models were used to assess the relationships between cognition, sNfL, T2 lesion volume (T2LV) and normalised regional brain volumes. RESULTS: Median age and Expanded Disability Status Score (EDSS) were 51 and 6.0. Each doubling of baseline sNfL was associated with a 0.010 [0.003–0.017] point per month faster decline in WASI Full Scale IQ Z-score (p = 0.008), independent of T2LV and normalised regional volumes. In contrast, lower baseline volume of the transverse temporal gyrus was associated with poorer current cognitive performance (0.362 [0.026–0.698] point reduction per mL, p = 0.035), but not change in cognition. The results were supported by secondary analyses on individual cognitive components. CONCLUSION: Elevated sNfL is associated with faster cognitive decline, independent of T2LV and regional normalised volumes.
format Online
Article
Text
id pubmed-9493411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-94934112022-09-23 Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial Williams, Thomas Tur, Carmen Eshaghi, Arman Doshi, Anisha Chan, Dennis Binks, Sophie Wellington, Henny Heslegrave, Amanda Zetterberg, Henrik Chataway, Jeremy Mult Scler Original Research Papers BACKGROUND: Cognitive impairment affects 50%–75% of people with secondary progressive multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate earlier intervention. OBJECTIVE: The main aim of this study was to assess the relationship between longitudinal changes in cognition and baseline serum neurofilament light chain (sNfL) in PwSPMS. In a multi-modal analysis, MRI variables were additionally included to determine if sNfL has predictive utility beyond that already established through MRI. METHODS: Participants from the MS-STAT trial underwent a detailed neuropsychological test battery at baseline, 12 and 24 months. Linear mixed models were used to assess the relationships between cognition, sNfL, T2 lesion volume (T2LV) and normalised regional brain volumes. RESULTS: Median age and Expanded Disability Status Score (EDSS) were 51 and 6.0. Each doubling of baseline sNfL was associated with a 0.010 [0.003–0.017] point per month faster decline in WASI Full Scale IQ Z-score (p = 0.008), independent of T2LV and normalised regional volumes. In contrast, lower baseline volume of the transverse temporal gyrus was associated with poorer current cognitive performance (0.362 [0.026–0.698] point reduction per mL, p = 0.035), but not change in cognition. The results were supported by secondary analyses on individual cognitive components. CONCLUSION: Elevated sNfL is associated with faster cognitive decline, independent of T2LV and regional normalised volumes. SAGE Publications 2022-08-09 2022-10 /pmc/articles/PMC9493411/ /pubmed/35946107 http://dx.doi.org/10.1177/13524585221114441 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Papers
Williams, Thomas
Tur, Carmen
Eshaghi, Arman
Doshi, Anisha
Chan, Dennis
Binks, Sophie
Wellington, Henny
Heslegrave, Amanda
Zetterberg, Henrik
Chataway, Jeremy
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
title Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
title_full Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
title_fullStr Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
title_full_unstemmed Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
title_short Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
title_sort serum neurofilament light and mri predictors of cognitive decline in patients with secondary progressive multiple sclerosis: analysis from the ms-stat randomised controlled trial
topic Original Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493411/
https://www.ncbi.nlm.nih.gov/pubmed/35946107
http://dx.doi.org/10.1177/13524585221114441
work_keys_str_mv AT williamsthomas serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT turcarmen serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT eshaghiarman serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT doshianisha serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT chandennis serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT binkssophie serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT wellingtonhenny serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT heslegraveamanda serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT zetterberghenrik serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial
AT chatawayjeremy serumneurofilamentlightandmripredictorsofcognitivedeclineinpatientswithsecondaryprogressivemultiplesclerosisanalysisfromthemsstatrandomisedcontrolledtrial